A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib)
Sponsor: Huazhong University of Science and Technology
This PHASE4 trial investigates Portal Vein Tumor Thrombus and is currently ongoing. Huazhong University of Science and Technology leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE4
▶ Show 1 earlier version
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Huazhong University of Science and Technology
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Wuhan, China